Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Suboxone

This page shows the latest Suboxone news and features for those working in and with pharma, biotech and healthcare.

Reckitt hammered by $1.4bn opioid settlement bill

Reckitt hammered by $1.4bn opioid settlement bill

The federal investigation centred on a former Reckitt pharmaceutical subsidiary – spun off in 2014 and renamed Indivior – and marketing practices it deployed for Suboxone between 2006 and 2015. ... Suboxone, which is based on the powerful opioid

Latest news

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    That would help counteract a major setback for the business in the US a few weeks back when it lost a patent infringement lawsuit involving its main product Suboxone (buprenorphine and ... RBP-6000 is a long-acting form of buprenorphine that can be

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for ... As it stands, those two companies remain blocked from

  • Reckitt to spin-off pharma unit as Indivior Reckitt to spin-off pharma unit as Indivior

    Demerged business will focus on opioid dependence product Suboxone. UK firm Reckitt Benckiser has confirmed detailed of its plans to demerge its pharmaceuticals business. ... RBP generates nearly all its revenues from Suboxone (buprenorphine and naloxone)

  • Reckitt Benckiser confirms pharma spin-off plans Reckitt Benckiser confirms pharma spin-off plans

    The pharma unit generates nearly all its revenues from Suboxone (buprenorphine and naloxone), used for the treatment of opioid dependence, and - while prescription volumes for the product grew in the US - ... RB Pharma is trying to expand its product

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    Its share price took a massive hit when it was indicted by the US Justice Department earlier this year over its Suboxone Film therapy for opioid and heroin addiction, but its ... Indivior discovered buprenorphine, sold it under the brand name Subutex to

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The US market for the treatment of opioid addiction is currently dominated by Indivor’s Suboxone, a film that is placed under the tongue once a day.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Indivior will not be without its challenges as sales of its off-patent opioid addiction treatment Suboxone continue to slump.

  • Pharma deals during July 2014 Pharma deals during July 2014

    However, with revenues falling by 8 per cent in H1 2014 as a result of US generic competition for Suboxone (the pharma unit's top selling drug), it remains to be

  • Pharma deals during May 2014 Pharma deals during May 2014

    All options continue to be considered. A capital markets solution is emerging as a strong option.” The difficulty is that Suboxone (for treatment of drug addiction) sales are being hit by

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links